3
IRUS Total
Downloads
  Altmetric

A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance

Title: A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance
Authors: Murphy, M
Erridge, S
Holvey, C
Coomber, R
Rucker, JJ
Sodergren, MH
Item Type: Journal Article
Abstract: BACKGROUND: Research on cannabis-based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high-quality evidence. Studies indicate a bidirectional relationship between generalized anxiety disorder (GAD) and sleep disruption, but it is unclear how this affects CBMP treatment outcomes. This study aims to compare the patient-reported outcome measures (PROMs) of patients prescribed CBMPs for GAD, with and without impaired sleep. METHODS: Changes in PROMs were recorded from baseline to 1, 3, 6, and 12 months between those with impaired or unimpaired sleep. Multivariate logistic regression was applied to compare factors associated with a clinically significant improvement in GAD-7 at 12 months. Secondary outcomes included adverse event incidence and frequency. RESULTS: Of the 302 patients that fit the inclusion criteria, mean GAD-7, single-item sleep quality, and EQ-5D-5L index values improved at all time points (p < 0.001). A relationship between sleep impairment and clinically significant changes in GAD-7 at 1 and 3 months was identified (p ≤ 0.01). On multivariate regression, only baseline GAD severity was associated with an increased likelihood of observing a clinically significant improvement in anxiety (p < 0.001). Seven hundred and seven (234%) adverse events were reported by 55 (18.21%) participants. CONCLUSIONS: This study observed an association between CBMP treatment and improvements in anxiety in patients with GAD. While patients with comorbid sleep disruption had greater improvements in anxiety, the differences were not maintained in a multivariate analysis. Baseline anxiety severity may be a predictor for CBMP treatment outcomes.
Issue Date: Mar-2024
Date of Acceptance: 28-Nov-2023
URI: http://hdl.handle.net/10044/1/109525
DOI: 10.1002/npr2.12407
ISSN: 2574-173X
Publisher: Wiley
Start Page: 129
End Page: 142
Journal / Book Title: Neuropsychopharmacology Reports
Volume: 44
Issue: 1
Copyright Statement: © 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Publication Status: Published
Conference Place: United States
Online Publication Date: 2023-12-28
Appears in Collections:Department of Surgery and Cancer
Faculty of Medicine
Institute of Global Health Innovation



This item is licensed under a Creative Commons License Creative Commons